Website%2520art%25205_edited_edited.jpg

Experienced. Dedicated. Determined.

The team at Meissa is dedicated and determined to advance life-saving vaccines against respiratory viruses. Our team brings more than 200 years of experience from discovery to commercial stage for vaccine development. We have completed more than 100 clinical trials and been involved in the development of 15 approved products. 

+

Leadership

+

Directors

+

Advisors

+

Investors

Publications

Polyvalent vaccines: High-maintenance heroes (Review), PLOS Pathogens, 2018.

A novel live attenuated RSV vaccine candidate, Nature Communications, 2016.

A polyvalent rhinovirus vaccine candidate, Nature Communications, 2016.

Publications

Polyvalent vaccines: High-maintenance heroes (Review), PLOS Pathogens, 2018.

A novel live attenuated RSV vaccine candidate, Nature Communications, 2016.

A polyvalent rhinovirus vaccine candidate, Nature Communications, 2016.

Publications

Polyvalent vaccines: High-maintenance heroes (Review), PLOS Pathogens, 2018.

A novel live attenuated RSV vaccine candidate, Nature Communications, 2016.

A polyvalent rhinovirus vaccine candidate, Nature Communications, 2016.

Meissa Vaccines, Inc.

© 2020 Meissa Vaccines, Inc.